What is a stock summary page? Click here for an overview.
Business Description
SCYNEXIS Inc
NAICS : 325412
SIC : 2834
ISIN : US8112922005
Description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.65 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | -0.8 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.29 | |||||
| Beneish M-Score | 6.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -46.4 | |||||
| 3-Year EBITDA Growth Rate | 30.5 | |||||
| 3-Year EPS without NRI Growth Rate | 33.3 | |||||
| 3-Year FCF Growth Rate | 38.3 | |||||
| 3-Year Book Growth Rate | 0.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 138.09 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.96 | |||||
| 9-Day RSI | 25.58 | |||||
| 14-Day RSI | 32.45 | |||||
| 3-1 Month Momentum % | 1.3 | |||||
| 6-1 Month Momentum % | -12.73 | |||||
| 12-1 Month Momentum % | -25.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3 | |||||
| Quick Ratio | 3 | |||||
| Cash Ratio | 2.46 | |||||
| Days Sales Outstanding | 218.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | 31.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -990.87 | |||||
| Net Margin % | -568.29 | |||||
| FCF Margin % | -640.92 | |||||
| ROE % | -33.15 | |||||
| ROA % | -19.56 | |||||
| ROIC % | -108.96 | |||||
| 3-Year ROIIC % | 77.85 | |||||
| ROC (Joel Greenblatt) % | -910.45 | |||||
| ROCE % | -23.86 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 8.32 | |||||
| PS Ratio | 11.45 | |||||
| PB Ratio | 0.61 | |||||
| Price-to-Tangible-Book | 0.61 | |||||
| EV-to-EBIT | 0.3 | |||||
| EV-to-EBITDA | 0.3 | |||||
| EV-to-Revenue | -1.22 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | 0.76 | |||||
| Price-to-GF-Value | 0.51 | |||||
| Price-to-Net-Current-Asset-Value | 0.91 | |||||
| Price-to-Net-Cash | 1.39 | |||||
| Earnings Yield (Greenblatt) % | 336.76 | |||||
| FCF Yield % | -67.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SCYNEXIS Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.746 | ||
| EPS (TTM) ($) | -0.44 | ||
| Beta | 0.63 | ||
| 3-Year Sharpe Ratio | -0.27 | ||
| 3-Year Sortino Ratio | -0.43 | ||
| Volatility % | 63.99 | ||
| 14-Day RSI | 32.45 | ||
| 14-Day ATR ($) | 0.038245 | ||
| 20-Day SMA ($) | 1.056358 | ||
| 12-1 Month Momentum % | -25.56 | ||
| 52-Week Range ($) | 0.861 - 3.07 | ||
| Shares Outstanding (Mil) | 37.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SCYNEXIS Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SCYNEXIS Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
SCYNEXIS Inc Frequently Asked Questions
What is SCYNEXIS Inc(LTS:0L49)'s stock price today?
The current price of LTS:0L49 is $0.86. The 52 week high of LTS:0L49 is $3.07 and 52 week low is $0.86.
When is next earnings date of SCYNEXIS Inc(LTS:0L49)?
The next earnings date of SCYNEXIS Inc(LTS:0L49) is 2025-03-28 Est..
Does SCYNEXIS Inc(LTS:0L49) pay dividends? If so, how much?
SCYNEXIS Inc(LTS:0L49) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers